Incannex Healthcare Commences DReAMzz Clinical Study for IHL-42X in OSA
The crossover dose optimization study aims to refine the dosing profile of the oral therapy and strengthen the design of the planned phase III development program.
Tag: Incannex
All
Latest
All
Latest
Incannex Provides Business Updates and Progress on OSA Drug Candidate in Phase 2/3 Trials
Incannex shares key developments, including the ongoing clinical trials for its lead product, IHL-42X, in development for the treatment of sleep apnea.
All
Latest
How Close Are We to Drug Therapy for Obstructive Sleep Apnea?
No oral pharmacologic treatment to maintain open airways for people with obstructive sleep apnea has been approved by the FDA—yet.
Incannex to Begin Investigational New Drug Opening Trial of IHL-42X in OSA
Incannex received approval from the US Food and Drug Administration for an Investigational New Drug opening pivotal IHL-42X phase 2/3 clinical trial in the United States as planned.
Read More
Incannex Submits IND for IHL-42X for Sleep Apnea
The IND application details the clinical trial protocol for the IND opening clinical trial, which is a multi-site phase 2/3 trial investigating IHL-42X, a cannabinoid combination product, for the treatment of OSA.
Read More
Incannex Taps Fortrea to Manage Phase 2/3 Trial for Sleep Apnea Drug Candidate
The phase 2/3 clinical trial will assess the safety and efficacy of IHL-42X, a cannabinoid combination product, in people with OSA who are intolerant, non-compliant, or naïve to CPAP.
Read More
Ethics Committee Greenlights Clinical Trial of IHL-42X for Sleep Apnea
The clinical trial will assess the pharmacokinetics and tolerability of the two active pharmaceutical ingredients in IHL-42X: dronabinol (THC) and acetazolamide.
Read More
Incannex Enlists Investigators for Phase 2/3 Study of IHL-42X for Sleep Apnea
IHL-42X, a cannabinoid combination product, is being developed as a pharmacological option for obstructive sleep apnea.
Read More
Dronabinol Is a Strong Contender for the First Sleep Apnea Pill
Dronabinol, synthetic THC, shows promise for the treatment of sleep apnea, and new advances from pharmaceutical companies suggest how it can be optimized.
Read More
Sleep Apnea Drug Candidate Developer Incannex to Acquire RLS Therapy Candidate Developer APIRx
The acquisition of APIRx will significantly strengthen Incannex’s position with regard to cannabinoid and psychedelic treatment development.
Read More